Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 16/20 | 0.81 |
| ▸ | ESR2 | Q92731 | 14/20 | 0.81 |
| ▸ | EBP | Q15125 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.48 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7105763 | 0.95 | ESR1 (0.72) | ESR1ESR2EBPSIGMAR1PSMB1 | |
| SCHEMBL7111259 | 0.94 | ESR1 (0.77) | ESR1ESR2EBPSIGMAR1PSMB1 | |
| Hydrochloric Acid SCHEMBL7153807 | 0.94 | ESR1 (0.71) | ESR1ESR2EBPSIGMAR1PSMB1 | |
| SCHEMBL7110414 | 0.94 | ESR1 (0.71) | ESR1ESR2EBPSIGMAR1PSMB1 | |
| SCHEMBL7108582 | 0.92 | ESR1 (0.88) | ESR1ESR2EBPSIGMAR1PSMB1 | |
| SCHEMBL7111413 | 0.92 | ESR1 (0.86) | ESR1ESR2PSMB1PSMB5PSMB2 | |
| SCHEMBL8476709 | 0.91 | ESR1 (0.67) | ESR1ESR2EBPSIGMAR1PSMB1 | |
| SCHEMBL7110896 | 0.91 | ESR1 (0.69) | ESR1ESR2EBPSIGMAR1PSMB1 | |
| SCHEMBL7112996 | 0.91 | ESR1 (0.66) | ESR1ESR2EBPSIGMAR1 | |
| SCHEMBL8477415 | 0.90 | ESR1 (0.65) | ESR1ESR2EBPSIGMAR1PSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | ELI LILLY AND COMPANY | 2003-05-29 | — | — | US | disclosed |
| EP-0826680-B1 | Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods of preparation thereof. | LILLY CO ELI (US) | 2001-10-24 | — | — | EP | disclosed |
| US-6020513-A | BONE DISORDERS | ELI LILLY AND COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| US-5958916-A | FOR INHIBITING BONE LOSS OR BONE RESORPTION | ELI LILLY AND COMPANY (US) | 1999-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100754-A1 | NAPHTHALENE COMPOUNDS, INTERMEDIATES, FORMULATIONS, AND METHODS | NDC1, SQLE, NQO1 | ESR1 1044/4885ESR2 2130/4885EBP 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.